Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18763| Title: | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. | Austin Authors: | Dubois, Bruno;Hampel, Harald;Feldman, Howard H;Scheltens, Philip;Aisen, Paul;Andrieu, Sandrine;Bakardjian, Hovagim;Benali, Habib;Bertram, Lars;Blennow, Kaj;Broich, Karl;Cavedo, Enrica;Crutch, Sebastian;Dartigues, Jean-François;Duyckaerts, Charles;Epelbaum, Stéphane;Frisoni, Giovanni B;Gauthier, Serge;Genthon, Remy;Gouw, Alida A;Habert, Marie-Odile;Holtzman, David M;Kivipelto, Miia;Lista, Simone;Molinuevo, José-Luis;O'Bryant, Sid E;Rabinovici, Gil D;Rowe, Christopher C ;Salloway, Stephen;Schneider, Lon S;Sperling, Reisa;Teichmann, Marc;Carrillo, Maria C;Cummings, Jeffrey;Jack, Cliff R | Affiliation: | Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France University Hospitals and University of Geneva, Geneva, Switzerland IRCCS Fatebenefratelli, Brescia, Italy University of British Columbia, Canada Department of Neurology and Alzheimer Center, VU University Medical Center and Neuroscience Campus, Amsterdam, The Netherlands University of Southern California San Diego, CA, USA UMR1027, INSERM, Université Toulouse III, Toulouse University Hospital, France IHU-A-ICM-Institut des Neurosciences translationnelles de Paris, Paris, France INSERM U1146-CNRS UMR 7371-UPMC UM CR2, Site Pitié-Salpêtrière, Paris, France Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Integrative and Experimental Genomics, University of Lübeck, Lübeck, Germany School of Public Health, Faculty of Medicine, Imperial College London, London, UK Clinical Neurochemistry Lab, Department of Neuroscience and Physiology, University of Gothenburg, Mölndal Hospital, Sahlgrenska University Hospital, Mölndal, Sweden Federal Institute for Drugs and Medical Devices, Bonn, Germany Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK INSERM U 1219, Université de Bordeaux, France University Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, Alzheimer-Prion Team Institut du Cerveau et de la Moelle (ICM), Paris, France McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada Fondation pour la Recherche sur Alzheimer, Hôpital Pitié-Salpêtrière, Paris, France Department of Clinical Neurophysiology/MEG Center, VU University Medical Center, Amsterdam Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Département de Médecine Nucléaire, Paris, France Department of Neurology, Washington University, Hope Center for Neurological Disorders, St. Louis, MO, USA Department of Neurology, Washington University, Knight Alzheimer's Disease Research Center, St. Louis, MO, USA Center for Alzheimer Research, Karolinska Institutet, Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden Institute of Clinical Medicine/ Neurology, University of Eastern Finland, Kuopio, Finland AXA Research Fund & UPMC Chair, Paris, France Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center, TX, USA Memory & Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA Department of Molecular Imaging, Austin Health, University of Melbourne, Australia Memory and Aging Program, Butler Hospital, Alpert Medical School of Brown University, USA Department of Neurology, Alpert Medical School of Brown University, USA Department of Psychiatry, Alpert Medical School of Brown University, USA Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA Harvard Medical School, Memory Disorders Unit, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, USA Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy The Alzheimer's Association Division of Medical & Scientific Relations, Chicago, USA Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA Department of Radiology, Mayo Clinic, Rochester MN, USA |
Issue Date: | Mar-2016 | Publication information: | Alzheimer's & dementia : the journal of the Alzheimer's Association 2016; 12(3): 292-323 | Abstract: | During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/18763 | DOI: | 10.1016/j.jalz.2016.02.002 | ORCID: | 0000-0003-3910-2453 | Journal: | Alzheimer's & dementia : the journal of the Alzheimer's Association | PubMed URL: | 27012484 | Type: | Journal Article | Subjects: | Alzheimer's disease Amyloid PET Asymptomatic Biomarkers Blood biomarkers CSF biomarkers Diagnostic criteria Genetics MRI Pathophysiology Preclinical Tau PET |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.